MYST3/CREBBP Rearranged Acute Myeloid Leukemia after Adjuvant Chemotherapy for Breast Cancer
Although rare, clinicians and patients must be aware that therapy related malignancies, specifically acute myeloid leukemia (AML), can occur as a complication of adjuvant chemotherapy for breast cancer. Vigilance for signs and symptoms is appropriate. AML with t (8;16) is a specific translocation le...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Case Reports in Oncological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2014/361748 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832545630200791040 |
|---|---|
| author | Arjun Gupta Mrinal M. Patnaik Harris V. Naina |
| author_facet | Arjun Gupta Mrinal M. Patnaik Harris V. Naina |
| author_sort | Arjun Gupta |
| collection | DOAJ |
| description | Although rare, clinicians and patients must be aware that therapy related malignancies, specifically acute myeloid leukemia (AML), can occur as a complication of adjuvant chemotherapy for breast cancer. Vigilance for signs and symptoms is appropriate. AML with t (8;16) is a specific translocation leading to formation of a fusion protein (MYST3/CREBBP). The MYST3/CREBBP AML tends to develop within 2 years of adjuvant chemotherapy, especially for breast cancer, without preceding myelodysplasia. It usually presents with disseminated intravascular coagulation and osteolytic lesions and has a poor prognosis despite aggressive resuscitation and therapy. With the increasing use of adjuvant chemotherapy for breast cancer, we are seeing a definite increase in the incidence of therapy related myelodysplastic syndromes and AML. One must keep this complication in mind while counseling and following up breast cancer patients who have received adjuvant chemotherapy. New osteolytic bone lesions in a patient with history of breast cancer do not necessarily mean metastatic disease and should be fully evaluated. |
| format | Article |
| id | doaj-art-269943f3705649858c48d6f63769ea7a |
| institution | Kabale University |
| issn | 2090-6706 2090-6714 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Oncological Medicine |
| spelling | doaj-art-269943f3705649858c48d6f63769ea7a2025-02-03T07:25:14ZengWileyCase Reports in Oncological Medicine2090-67062090-67142014-01-01201410.1155/2014/361748361748MYST3/CREBBP Rearranged Acute Myeloid Leukemia after Adjuvant Chemotherapy for Breast CancerArjun Gupta0Mrinal M. Patnaik1Harris V. Naina2Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USADivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55902, USADepartment of Hematology Oncology, University of Texas Southwestern Medical Center, Seay Biomedical Building, 2201 Inwood Road, Dallas, TX 75390, USAAlthough rare, clinicians and patients must be aware that therapy related malignancies, specifically acute myeloid leukemia (AML), can occur as a complication of adjuvant chemotherapy for breast cancer. Vigilance for signs and symptoms is appropriate. AML with t (8;16) is a specific translocation leading to formation of a fusion protein (MYST3/CREBBP). The MYST3/CREBBP AML tends to develop within 2 years of adjuvant chemotherapy, especially for breast cancer, without preceding myelodysplasia. It usually presents with disseminated intravascular coagulation and osteolytic lesions and has a poor prognosis despite aggressive resuscitation and therapy. With the increasing use of adjuvant chemotherapy for breast cancer, we are seeing a definite increase in the incidence of therapy related myelodysplastic syndromes and AML. One must keep this complication in mind while counseling and following up breast cancer patients who have received adjuvant chemotherapy. New osteolytic bone lesions in a patient with history of breast cancer do not necessarily mean metastatic disease and should be fully evaluated.http://dx.doi.org/10.1155/2014/361748 |
| spellingShingle | Arjun Gupta Mrinal M. Patnaik Harris V. Naina MYST3/CREBBP Rearranged Acute Myeloid Leukemia after Adjuvant Chemotherapy for Breast Cancer Case Reports in Oncological Medicine |
| title | MYST3/CREBBP Rearranged Acute Myeloid Leukemia after Adjuvant Chemotherapy for Breast Cancer |
| title_full | MYST3/CREBBP Rearranged Acute Myeloid Leukemia after Adjuvant Chemotherapy for Breast Cancer |
| title_fullStr | MYST3/CREBBP Rearranged Acute Myeloid Leukemia after Adjuvant Chemotherapy for Breast Cancer |
| title_full_unstemmed | MYST3/CREBBP Rearranged Acute Myeloid Leukemia after Adjuvant Chemotherapy for Breast Cancer |
| title_short | MYST3/CREBBP Rearranged Acute Myeloid Leukemia after Adjuvant Chemotherapy for Breast Cancer |
| title_sort | myst3 crebbp rearranged acute myeloid leukemia after adjuvant chemotherapy for breast cancer |
| url | http://dx.doi.org/10.1155/2014/361748 |
| work_keys_str_mv | AT arjungupta myst3crebbprearrangedacutemyeloidleukemiaafteradjuvantchemotherapyforbreastcancer AT mrinalmpatnaik myst3crebbprearrangedacutemyeloidleukemiaafteradjuvantchemotherapyforbreastcancer AT harrisvnaina myst3crebbprearrangedacutemyeloidleukemiaafteradjuvantchemotherapyforbreastcancer |